Understanding how nairovirus affects the body's immune response
Origin of the innate immunity suppression caused by nairovirus' protease activity
This study is looking at how the Crimean-Congo hemorrhagic fever virus tricks our immune system so it can cause more harm, and it's aimed at helping people understand this virus better to find new ways to treat or prevent it.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Riverside NIH-funded |
| Lab location | 1 site (Riverside, United States) |
| Project ID | NIH-10898165 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which the nairovirus, specifically the Crimean-Congo hemorrhagic fever virus (CCHFV), suppresses the innate immune response in humans. The study focuses on a viral protease that interferes with host cellular pathways, potentially leading to severe symptoms such as fever and hemorrhaging. By examining the viral proteins and their interactions with the immune system, researchers aim to uncover critical insights that could inform future treatments or preventive measures. The research is particularly relevant given the increasing spread of CCHFV to new regions and the lack of effective vaccines or therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have been exposed to CCHFV or are at risk of infection due to travel to endemic regions.
Not a fit: Patients who are not at risk of nairovirus infections or those with existing immunity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapeutic strategies or vaccines to combat nairovirus infections.
How similar studies have performed: While the specific approach of targeting nairovirus protease activity is novel, similar research on viral immune evasion has shown promise in other contexts.
Where this research is happening
Riverside, United States
- University of California Riverside — Riverside, United States (Active)
Researchers
- Principal investigator: Pegan, Scott Dusan — University of California Riverside
- Study coordinator: Pegan, Scott Dusan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.